Clinical Trials
GALE
A Phase III, Open-Label, Multi-Centre, Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in Subjects with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD).
Overview
A Phase III, Open-Label, Multi-Centre, Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in Subjects with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD).
- Principal Investigator
Professor Robyn Guymer AM
A Phase III, Open-Label, Multi-Centre, Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in Subjects with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD).
- Principal Investigator
Learn more
View this study on ClinicalTrials.gov
See the ClinicalTrials.gov database listing for more detailed information about this study.